Noticia

The AACR-AstraZeneca -MedImmune Clinical Immuno-oncology Research Training Fellowships Program is designed to provide training opportunities for physician-scientists with real-world experience in early-stage or late-stage clinical development at the facilities of AstraZeneca and its Affiliates. It is anticipated that two fellowships will be funded.

Applicants must have a medical degree (including MD, DO, or MD/PhD) in a related field, and not currently be a candidate for a further doctoral degree. Additionally, at the start of the grant term, eligible applicants must have completed their most recent residency within the past 5 years.

Grant Amount: Each fellowship provides $100,000.

Application deadline: July 6, 2018 at 1:00 p.m. U.S. Eastern Time.

Physician-scientists often receive world-class training in patient care, including the newest technologies and approaches to diagnose and treat disease. However, these clinicians also require additional training in laboratory and clinic-based research, in order to stay up-to-date with the pace of medical progress. As such, many fellowship programs offer a “research” year to these young physician-scientists to ensure they have sufficient expertise to contribute to laboratory-based research projects or clinical trials that will advance medical practice and improve patient outcomes.

Many of these training experiences occur in an academic setting, and are focused mainly on retrospective clinical trials, or basic, laboratory-based science; there is a paucity of training opportunities for clinical fellows to gain expertise in conducting an early-stage or a late-stage clinical trial. The AACR-AstraZeneca-MedImmune Clinical Immuno-oncology Research Training Fellowships Program is designed to fill this knowledge gap by providing physician-scientists with real-world experience in early-stage or late-stage clinical development at the facilities of AstraZeneca and its Affiliates.

Each fellowship provides $100,000 over one year to support the salary and benefits of the fellow while working on a mentored research project at one of facilities of AstraZeneca and its Affiliates. Outstanding fellows may be invited to extend the fellowship for an additional year.

It is anticipated that two fellowships will be funded, one for early-stage research and one for late-stage clinical development in immuno-oncology research.

More information in the next link:

http://www.aacr.org/Funding/Pages/Funding-Detail.aspx?ItemID=74#.WvQFJKSFN9O